JP2025508695A - がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用 - Google Patents

がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用 Download PDF

Info

Publication number
JP2025508695A
JP2025508695A JP2024547460A JP2024547460A JP2025508695A JP 2025508695 A JP2025508695 A JP 2025508695A JP 2024547460 A JP2024547460 A JP 2024547460A JP 2024547460 A JP2024547460 A JP 2024547460A JP 2025508695 A JP2025508695 A JP 2025508695A
Authority
JP
Japan
Prior art keywords
cancer
therapy
individual
mutations
tmb
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547460A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508695A5 (https=
Inventor
リオン ピー． グラフ，
アレクサ シュロック，
リチャード シェン ポー ファン，
ジェフリー アール． オックスナード，
Original Assignee
ファウンデーション・メディシン・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファウンデーション・メディシン・インコーポレイテッド filed Critical ファウンデーション・メディシン・インコーポレイテッド
Publication of JP2025508695A publication Critical patent/JP2025508695A/ja
Publication of JP2025508695A5 publication Critical patent/JP2025508695A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024547460A 2022-02-11 2023-02-10 がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用 Pending JP2025508695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263309449P 2022-02-11 2022-02-11
US63/309,449 2022-02-11
US202263335079P 2022-04-26 2022-04-26
US63/335,079 2022-04-26
PCT/US2023/062434 WO2023154895A1 (en) 2022-02-11 2023-02-10 Use of tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy effectiveness in cancer treatment

Publications (2)

Publication Number Publication Date
JP2025508695A true JP2025508695A (ja) 2025-04-10
JP2025508695A5 JP2025508695A5 (https=) 2026-02-16

Family

ID=87565160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547460A Pending JP2025508695A (ja) 2022-02-11 2023-02-10 がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用

Country Status (4)

Country Link
US (1) US20250146078A1 (https=)
EP (1) EP4476368A4 (https=)
JP (1) JP2025508695A (https=)
WO (1) WO2023154895A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026060295A1 (en) * 2024-09-12 2026-03-19 Omniseq, Inc. Cancer testis antigen burden (ctab) as a biomarker of tumor-associated antigens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038712A1 (en) * 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
EP3601355A1 (en) * 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
WO2021092221A1 (en) * 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy

Also Published As

Publication number Publication date
EP4476368A1 (en) 2024-12-18
WO2023154895A1 (en) 2023-08-17
EP4476368A4 (en) 2026-03-04
US20250146078A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
Gulhati et al. Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
JP7851251B2 (ja) 遺伝子サンプリングにおける統計的バイアスの軽減
US20240410016A1 (en) Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
US20250019770A1 (en) Circulating tumor dna fraction and uses thereof
JP2026049725A (ja) 循環腫瘍ｄｎａの分析を介した分子疾患評価のための方法およびシステム
US20230295734A1 (en) Bcor rearrangements and uses thereof
US20250201339A1 (en) Use of combined cd274 copy number changes and tmb to predict response to immunotherapies
US20250146076A1 (en) Alk gene fusions and uses thereof
US20250101534A1 (en) Use of spop mutations as a predictive biomarker
US20250003009A1 (en) Fragment consensus methods for ultrasensitive detection of aberrant methylation
US20240263240A1 (en) Cd274 mutations for cancer treatment
US20250104876A1 (en) Aneuploidy biomarkers associated with response to anti-cancer therapies
JP2025508695A (ja) がん治療における免疫チェックポイント阻害剤対化学療法の有効性のための予測バイオマーカーとしての腫瘍変異負荷の使用
EP4359570A1 (en) Methods of using somatic hla-i loh to predict response of immune checkpoint inhibitor-treated patients with lung cancer
US20250230243A1 (en) Prediction of chemotherapy-free immunotherapy effectiveness for patients with cancers
CN118679268A (zh) 肿瘤突变负荷作为针对癌症治疗中的免疫检查点抑制剂与化学疗法有效性的预测性生物标志物的用途
WO2025122856A1 (en) Use of fibroblast growth factor receptor 3 mutations and tumor mutational burden to predict response to immunotherapies
WO2025024258A2 (en) Ebv status as a predictor of response to immunotherapy
WO2025122504A1 (en) Esr1 mutations, esr1 co-occurring mutations, and uses thereof
WO2024050437A2 (en) Methods for evaluating clonal tumor mutational burden
WO2026030539A1 (en) Alk mutations and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260205